Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body.


Journal

Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448

Informations de publication

Date de publication:
09 2020
Historique:
received: 20 05 2020
revised: 14 06 2020
accepted: 16 06 2020
pubmed: 21 7 2020
medline: 2 10 2020
entrez: 21 7 2020
Statut: ppublish

Résumé

A knowledge-based cybernetic framework model representing the dynamics of SARS-CoV-2 inside the human body has been studied analytically and in silico to explore the pathophysiologic regulations. The following modeling methodology was developed as a platform to introduce a predictive tool supporting a therapeutic approach to Covid-19 disease. A time-dependent nonlinear system of ordinary differential equations model was constructed involving type-I cells, type-II cells, SARS-CoV-2 virus, inflammatory mediators, interleukins along with host pulmonary gas exchange rate, thermostat control, and mean pressure difference. This formalism introduced about 17 unknown parameters. Estimating these unknown parameters requires a mathematical association with the in vivo sparse data and the dynamic sensitivities of the model. The cybernetic model can simulate a dynamic response to the reduced pulmonary alveolar gas exchange rate, thermostat control, and mean pressure difference under a very critical condition based on equilibrium (steady state) values of the inflammatory mediators and system parameters. In silico analysis of the current cybernetical approach with system dynamical modeling can provide an intellectual framework to help experimentalists identify more active therapeutic approaches.

Identifiants

pubmed: 32686248
doi: 10.1002/rmv.2140
pmc: PMC7404608
doi:

Substances chimiques

Acute-Phase Proteins 0
Anti-Inflammatory Agents 0
Antiviral Agents 0
Cytokines 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2140

Subventions

Organisme : University College London
Pays : International
Organisme : World Health Organization
Pays : International

Informations de copyright

© 2020 John Wiley & Sons, Ltd.

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Methods Mol Biol. 2020;2099:195-204
pubmed: 31883097
Mediators Inflamm. 2017;2017:4327237
pubmed: 29038619
Anesthesiology. 1997 Mar;86(3):532-7
pubmed: 9066318
J Virol. 2018 Oct 12;92(21):
pubmed: 30111569
Clin Chem. 2005 Dec;51(12):2333-40
pubmed: 16195357
Cell Host Microbe. 2020 May 13;27(5):704-709.e2
pubmed: 32259477
Rev Med Virol. 2020 Sep;30(5):e2140
pubmed: 32686248
Am J Respir Cell Mol Biol. 2011 Sep;45(3):582-91
pubmed: 21239608
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
Am J Respir Cell Mol Biol. 2014 Apr;50(4):767-76
pubmed: 24191670
Am J Physiol Lung Cell Mol Physiol. 2013 Sep 15;305(6):L409-18
pubmed: 23831617
Lancet. 2020 Mar 28;395(10229):1039-1046
pubmed: 32192580
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Am J Respir Cell Mol Biol. 2013 Jun;48(6):742-8
pubmed: 23418343
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Dtsch Med Wochenschr. 2020 May;145(10):670-674
pubmed: 32344440
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Infect Dis Poverty. 2020 Feb 28;9(1):24
pubmed: 32111262
Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L536-46
pubmed: 21724858
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748

Auteurs

Asit Saha (A)

The Lambda Academy of Science, Success, Western Australia, Australia.

Barsha Saha (B)

The Lambda Academy of Science, Success, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH